<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05045248</url>
  </required_header>
  <id_info>
    <org_study_id>BIO-2019-0027</org_study_id>
    <nct_id>NCT05045248</nct_id>
  </id_info>
  <brief_title>Efficacy of Apraclonidine Eye Drops in the Treatment of Ptosis Secondary to Myasthenia Gravis</brief_title>
  <official_title>Efficacy of Apraclonidine Eye Drops in the Treatment of Ptosis Secondary to Myasthenia Gravis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>American University of Beirut Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>American University of Beirut Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is aimed at assessing the efficacy of Apraclonidine eye drops in the treatment of&#xD;
      ptosis secondary to myasthenia gravis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The rationale behind using Apraclonidine is that it acts on Muller's muscle which is a&#xD;
      sympathetic-innervated muscle. As such, this muscle is expected to be spared from the effects&#xD;
      of the autoantibodies that attack the postsynaptic portion of the neuromuscular junction in&#xD;
      myasthenia gravis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2020</start_date>
  <completion_date type="Actual">April 15, 2021</completion_date>
  <primary_completion_date type="Actual">April 15, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in palpebral fissure height (PF)</measure>
    <time_frame>Before administration, at 1, 5, 30, and 60 minutes after administration</time_frame>
    <description>Change in PF measurements</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in marginal reflex distance-1 (MRD1)</measure>
    <time_frame>Before administration, at 1, 5, 30, and 60 minutes after administration</time_frame>
    <description>Change in MRD1 measurements</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in marginal reflex distance-2 (MRD2)</measure>
    <time_frame>Before administration, at 1, 5, 30, and 60 minutes after administration</time_frame>
    <description>Change in MRD2 measurements</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in levator function (LF)</measure>
    <time_frame>Before administration, at 1, 5, 30, and 60 minutes after administration</time_frame>
    <description>Change in LF measurements</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Myasthenia Gravis</condition>
  <condition>Ocular Myasthenia Gravis</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each patient is administered 2 drops of Apraclonidine 0.5% solution to the most affected eye. Objective measurements of ptosis will be taken before drug administration and at 1, 5, 30, 60 minutes after drug administration in order to analyze any change in ptosis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apraclonidine Hcl 0.5% Oph Soln</intervention_name>
    <description>Each patient is administered 2 drops of Apraclonidine 0.5% solution to the most affected eye</description>
    <arm_group_label>Patients</arm_group_label>
    <other_name>Iopidine 0.5%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged 18 or older with a diagnosis of ocular or generalized myasthenia gravis&#xD;
             with ocular involvement.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients receiving mono-amino-oxidase inhibitors.&#xD;
&#xD;
          -  Patients with history of hypertension, cardiac, or cerebrovascular disease.&#xD;
&#xD;
          -  Women with confirmed pregnancy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johnny Salameh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>American University of Beirut Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>American University of Beirut Medical Center</name>
      <address>
        <city>Beirut</city>
        <zip>1107</zip>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Lebanon</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 29, 2021</study_first_submitted>
  <study_first_submitted_qc>September 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2021</study_first_posted>
  <last_update_submitted>September 6, 2021</last_update_submitted>
  <last_update_submitted_qc>September 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>American University of Beirut Medical Center</investigator_affiliation>
    <investigator_full_name>Johnny Salameh</investigator_full_name>
    <investigator_title>Associate Professor, Department of Neurology</investigator_title>
  </responsible_party>
  <keyword>myasthenia gravis</keyword>
  <keyword>ocular myasthenia</keyword>
  <keyword>apraclonidine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myasthenia Gravis</mesh_term>
    <mesh_term>Muscle Weakness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apraclonidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

